Access and Evidence: Implications of the EPO Safety Debate (Part 2)
This article was originally published in RPM Report
It looks like CMS is making its restrictive coverage policy on Aranesp and Procrit stick. That is a big hit to Amgen and J&J. It is also an important precedent for other manufacturers: CMS is demonstrating that it can deny coverage based on the absence of evidence-even when the therapy is the standard of care.
You may also be interested in...
The final coverage decision for Lilly’s Amyvid sticks with the proposal to limit payment to use in clinical trials. That is a setback for Lilly, but reinforces the Medicare agency’s commitment to the Coverage with Evidence Development pathway.
On July 21, Roche reported strong first half sales of Lucentis. It was all downhill from there.
CMS’ coverage of cancer drugs isn’t as automatic as you think. Here’s how the Medicare agency sees it.